Results 191 to 200 of about 30,319 (222)

CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses. [PDF]

Sci Adv
Nguyen KA, Liu Z, Davies JS, McIntosh CP, Draper LM, Norberg SM, Rae Z, Achar SR, Altan-Bonnet G, Zhang L, Wu X, Meyer TJ, Kelly MC, Taylor N, Hinrichs CS, Ishii K.   +15 more
europepmc   +1 more source

Polymer lipid hybrid nanoparticles for phytochemical delivery: challenges, progress, and future prospects. [PDF]

Beilstein J Nanotechnol
Rahat I, Yadav P, Singhal A, Fareed M, Purushothaman JR, Aslam M, Balaji R, Patil-Shinde S, Rizwanullah M.   +8 more
europepmc   +1 more source

INTASYL self-delivering RNAi decreases TIGIT expression, enhancing NK cell cytotoxicity: a potential application to increase the efficacy of NK adoptive cell therapy against cancer. [PDF]

Cancer Immunol Immunother
Maxwell M, Yan D, Rivest B, Boone A, Cardia J, Noessner E.   +5 more
europepmc   +1 more source

TP53‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, EarlyView.
ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah, Daniel A. Arber, Devendra K. Hiwase   +2 more
wiley   +1 more source

Antitumor Activities of a Humanized Cancer-Specific Anti-HER2 Monoclonal Antibody, humH₂Mab-250 in Human Breast Cancer Xenografts. [PDF]

Int J Mol Sci
Kaneko MK, Suzuki H, Ohishi T, Nakamura T, Yanaka M, Tanaka T, Kato Y.   +6 more
europepmc   +1 more source

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives

American Journal of Hematology, EarlyView.
ABSTRACT Myelofibrosis (MF) is a myeloproliferative neoplasm that is accompanied by driver JAK2, CALR, or MPL mutations in more than 90% of cases, leading to constitutive activation of the JAK–STAT pathway. MF is a multifaceted disease characterized by trilineage myeloid proliferation with prominent megakaryocyte atypia and bone marrow fibrosis, as ...
Giuseppe G. Loscocco, Paola Guglielmelli
wiley   +1 more source

Treatment of thrombotic microangiopathy associated with systemic lupus erythematosus with low-dose rituximab as an induction agent and belimumab as a maintenance agent. [PDF]

BMC Pediatr
Yang Z, Liu S, Zong Z, Li Q, Yu L, Sun S.   +5 more
europepmc   +1 more source

Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta‐Analysis

American Journal of Hematology, EarlyView.
ABSTRACT In the Phase 3 DREAMM‐7 study of patients with relapsed/refractory multiple myeloma (RRMM) who received ≥ 1 prior therapy, belantamab mafodotin plus bortezomib and dexamethasone (BVd) demonstrated a progression‐free survival (PFS) benefit versus daratumumab plus bortezomib and dexamethasone (DVd).
Joshua Richter, Ajay Nooka, Paula Rodríguez‐Otero, Fredrik Schjesvold, Eirini Katodritou, Emily Combe, Marianne Scott, Leanne Cooper, Indeg Sly, Nick Ballew, Jacopo Bitetti, Natalie Boytsov, Molly Purser, Simon McNamara   +13 more
wiley   +1 more source

Compositional variation in eye-infiltrating immune cells distinguishes human uveitis subtypes. [PDF]

iScience
Concepcion C, Xia Y, Korshunova Y, Bligard GW, Taylor A, Paley MA, Ruzycki PA, Hassman LM.   +7 more
europepmc   +1 more source

Persistent Eosinophilic Inflammation Is Not a Feature of Type 2 CRS Patients Failing Anti‐IL‐5R Therapy and Requiring Class Switching to Anti‐IL‐4/13

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Type 2 inflammation dominates eosinophilic chronic rhinosinusitis (eCRS) and adult onset asthma. IL‐4, ‐5, and ‐13 are prominent disease mediators. Disease control can be achieved with biologic therapies. However, despite some patients entering remission, others experience poor control. Aim We aimed to describe eCRS patients treated
Peta‐Lee Sacks, Christian M Meerwein, Peter Earls, Cedric Thiel, Christine Choy, Raewyn G Campbell, Raymond Sacks, Larry Kalish, Richard J Harvey   +8 more
wiley   +1 more source